



**Department of Vermont Health Access
Pharmacy Benefits Management Program
*DUR Board Meeting Agenda***

February 21, 2012 6:30 – 9:00 p.m.

- 1. Executive Session 6:30 - 7:00**
 - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements (as provided by 33 VSA § 1998(f)(2))

- 2. Introductions and Approval of DUR Board Minutes 7:00 - 7:05**

(Public Comment Prior to Board Action)

- 3. DVHA Pharmacy Administration Updates 7:05 - 7:15**
 - Senator Grassley Report
 - CMS Updates
 - Single Formulary

- 4. Medical Director Update 7:15 - 7:20**
 - Clinical Programs Update
 - Prescriber Comments

- 5. Follow-up Items from Previous Meetings 7:20 - 7:35**
 - Citalopram > 40 mg/day
 - Provigil[®]
 - Started and Stabilized in Mental Health categories (samples)

- 6. RetroDUR/DUR 7:35 - 7:50**
 - Opiate Agonists/Opiate Combination Utilization 2007 - 2011
 - Psychotropic Medication Use in Children SFY 2009 – 2011
 - DUR Edits – Refill Too Soon and Ingredient Duplication

- 7. Clinical Update: Drug Reviews 7:50 – 8:20**

(Public comment prior to Board action)

Abbreviated Drug Reviews

 - Lotemax[®] (loteprednol etabonate 0.5%) Ophthalmic Ointment
 - Nucynta ER[®] (tapentadol) Extended Release Tablet

Full New Drug Reviews

 - Brilinta[®] (ticagrelor) Oral Tablet
 - Firazyr[®] (icatibant) Prefilled Syringe for Subcutaneous Injection
 - Solesta[®] Gel Prefilled Syringe for Submucosal Injection
 - Viibryd[®] (vilazodone hydrochloride) Oral Tablet

- 8. Therapeutic Drug Classes – Periodic Review** **8:20 – 8:30**
(Public comment prior to Board action)
Class review documents available on DVHA web site 2/21/2012 @ 12 Noon
- Anti-Fungals - Oral

 - Hepatitis C Medications
 - Hepatitis C Antivirals
 - Hepatitis C Protease Inhibitors (brief discussion – previously reviewed)
 - Interferons
 - Pegylated Interferons
- 9. New Managed Therapeutic Drug Classes** **8:30 – 8:35**
(Public comment prior to Board action)
- Antihypertensives: Alpha Blockers
- 10. Review of Newly-Developed/Revised Clinical Coverage Criteria and/or Preferred Products** **8:35 – 8:45**
(Public comment prior to Board action)
- Antidepressants: SNRIs
- 11. General Announcements** **8:45– 8:55**
Selected FDA Safety Alerts
- Proton Pump Inhibitors – Drug Safety Communication – Clostridium difficile associated diarrhea
 - Tysabri® - Drug Safety Communication – Update of Risk Factors for PML
 - Victrelis® - Drug Safety Communication – Important Drug Interaction with Certain HIV Protease Inhibitors
- 12. Adjourn** **9:00**